Inovio Pharmaceuticals Inc

Precigen has received FDA platform technology designation for its AdenoVerse immunotherapeutic platform, a move management says could benefit the investigational candidate PRGN-2009 across multiple HPV-associated cancers, including cervical and oropharyngeal cancers. PRGN-2009 is being evaluated in a multicenter phase II study in combination with Merck's Keytruda in patients with recurrent or metastatic cervical cancer, and Precigen plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026. The designation comes as Precigen's commercial-stage Papzimeos, the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis, generated $74.6 million in revenues in the first six months of 2026, with product revenues more than doubling sequentially in the second quarter. A marketing authorization application for Papzimeos in adults with recurrent respiratory papillomatosis is under review in Europe, and the drug holds seven years of FDA market exclusivity through Aug. 14, 2032. Rival Inovio Pharmaceuticals is developing INO-3107 for recurrent respiratory papillomatosis, with an FDA decision expected on Oct. 30, 2026.